283 related articles for article (PubMed ID: 19451656)
1. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older.
Ibrahim HN; Ishani A; Guo H; Gilbertson DT
Nephrol Dial Transplant; 2009 Oct; 24(10):3138-43. PubMed ID: 19451656
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
3. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
4. Transfusion burden among patients with chronic kidney disease and anemia.
Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
[TBL] [Abstract][Full Text] [Related]
5. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
[TBL] [Abstract][Full Text] [Related]
6. Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia.
Collins AJ; Guo H; Gilbertson DT; Bradbury BD
Nephron Clin Pract; 2009; 111(2):c141-8. PubMed ID: 19147996
[TBL] [Abstract][Full Text] [Related]
7. [Transfusion requirements in chronic kidney disease].
Frimat L
Transfus Clin Biol; 2008 Nov; 15(5):214-6. PubMed ID: 18938100
[TBL] [Abstract][Full Text] [Related]
8. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
Lafeuille MH; Bailey RA; Vekeman F; Kilpatrick BS; Senbetta M; Piech CT; Lefebvre P
Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
[TBL] [Abstract][Full Text] [Related]
9. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
11. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.
Carrero JJ; Bárány P; Yilmaz MI; Qureshi AR; Sonmez A; Heimbürger O; Ozgurtas T; Yenicesu M; Lindholm B; Stenvinkel P
Nephrol Dial Transplant; 2012 Feb; 27(2):709-15. PubMed ID: 21617198
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005.
Ibrahim HN; Ishani A; Foley RN; Guo H; Liu J; Collins AJ
Am J Kidney Dis; 2008 Dec; 52(6):1115-21. PubMed ID: 18823686
[TBL] [Abstract][Full Text] [Related]
13. Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting.
Germain MJ
Consult Pharm; 2008 Mar; 23 Suppl A():11-7. PubMed ID: 18454575
[TBL] [Abstract][Full Text] [Related]
14. Iron therapy in chronic kidney disease: current controversies.
Kovesdy CP; Kalantar-Zadeh K
J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
[TBL] [Abstract][Full Text] [Related]
15. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
Othman M; Kawar B; El Nahas AM
Nephron Clin Pract; 2009; 113(1):c16-23. PubMed ID: 19590231
[TBL] [Abstract][Full Text] [Related]
16. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
17. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
18. Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data.
Rasu RS; Manley HJ; Crawford T; Balkrishnan R
Clin Ther; 2007 Jul; 29(7):1524-34. PubMed ID: 17825703
[TBL] [Abstract][Full Text] [Related]
19. Anemia in renal disease: diagnosis and management.
Lankhorst CE; Wish JB
Blood Rev; 2010 Jan; 24(1):39-47. PubMed ID: 19833421
[TBL] [Abstract][Full Text] [Related]
20. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]